Cited by 1,499Inflammatory Bowel DiseaseGut microbiota and healthMicroscopic Colitis

Fecal Microbiota Transplantation Induces Remission in Patients With Active Ulcerative Colitis in a Randomized Controlled Trial

Open access
Moayyedi, Paul, Surette, Michael G., Kim, Peter T., Libertucci, Josie, Wolfe, Melanie, Onischi, Catherine, Armstrong, David, Marshall, John K. +3 more·2015·Gastroenterology

Abstract

Background & aims Ulcerative colitis (UC) is difficult to treat, and standard therapy does not always induce remission. Fecal microbiota transplantation (FMT) is an alternative approach that induced remission in small series of patients with active UC. We investigated its safety and efficacy in a placebo-controlled randomized trial.Methods We performed a parallel study of patients with active UC without infectious diarrhea. Participants were examined by flexible sigmoidoscopy when the study began and then were randomly assigned to groups that received FMT (50 mL, via enema, from healthy anonymous donors; n = 38) or placebo (50 mL water enema; n = 37) once weekly for 6 weeks. Patients, clinicians, and investigators were blinded to the groups. The primary outcome was remission of UC, defined as a Mayo score ≤2 with an endoscopic Mayo score of 0, at week 7. Patients provided stool samples when the study began and during each week of FMT for microbiome analysis. The trial was stopped early for futility by the Data Monitoring and Safety Committee, but all patients already enrolled in the trial were allowed to complete the study.Results Seventy patients completed the trial (3 dropped out from the placebo group and 2 from the FMT group). Nine patients who received FMT (24%) and 2 who received placebo (5%) were in remission at 7 weeks (a statistically significant difference in risk of 17%; 95% confidence interval, 2%-33%). There was no significant difference in adverse events between groups. Seven of the 9 patients in remission after FMT received fecal material from a single donor. Three of the 4 patients with UC ≤1 year entered remission, compared with 6 of 34 of those with UC >1 year (P = .04, Fisher's exact test). Stool from patients receiving FMT had greater microbial diversity, compared with baseline, than that of patients given the placebo (P = .02, Mann-Whitney U test).Conclusions FMT induces remission in a significantly greater percentage of patients with active UC than placebo, with no difference in adverse events. Fecal donor and time of UC appear to affect outcomes. ClinicalTrials.gov Number: NCT01545908.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1053/j.gastro.2015.04.001

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • In two randomized controlled trials of UC patients, FMT responders showed a higher similarity to their donors than nonresponders.

    “Finally, in two randomized controlled trials of UC patients, FMT responders showed a higher similarity to their donors than nonresponders. 61,62”
  • A second randomised controlled trial in ulcerative colitis, using weekly faecal enemas from healthy donors or placebo enemas for 6 weeks, demonstrated remission in a greater percentage of patients given FMT compared with the control group given water enema.

    “A second trial, in which patients with UC were randomised to weekly faecal enemas from healthy donors or placebo enemas for 6 weeks, demonstrated remission in a greater percentage of patients given FMT compared with the control group (given water enema).77”

    From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [77]

  • Two randomised controlled trials of FMT in ulcerative colitis since that meta-analysis show discrepant results.

    “Since that meta-analysis, two randomised controlled trials in UC show discrepant results.”

    From The gut microbiota and host health: a new clinical frontier (2016) · cites this paper as [77]

  • Flares of FMT in patients with both UC and Crohn's disease have been described, raising questions about safety and potential to worsen disease in some patients.

    “Furthermore, flares of FMT in patients with both UC and CD have been described,43, 75, 76 raising important questions around safety and the potential to worsen disease in some patients.”
  • Fecal microbiota transplantation from healthy hosts is positively correlated with disease reversal, especially those stemming from gut barrier dysfunction like IBD, IBS, celiac disease, and Clostridium difficile infections.

    “Studies have revealed that fecal microbiota transplantation (FMT) from healthy hosts are positively correlated with disease reversal, especially those stemming from gut barrier dysfunction like IBD, IBS, celiac disease, and Clostridium difficile infections.19,20”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Moayyedi, P., Surette, M. G., Kim, P. T., Libertucci, J., Wolfe, M., Onischi, C., Armstrong, D., Marshall, J. K., Kassam, Z., Reinisch, W., & Lee, C. H.
Affiliations
  • McMaster University (CA)
  • University of Guelph (CA)
  • Massachusetts Institute of Technology (US)
Corresponding author
  • Moayyedi, Paul
  • Lee, Christine H.
Venue
Gastroenterology
Publisher
Elsevier BV
Published
2015-07
Volume
149
Issue
1
Pages
102-109.e6
ISSN
0016-5085 (ISSN-L)
OpenAlex
W2078754045
Cited by
1,499
References
35
Citations by year
2026: 62 · 2025: 111 · 2024: 121 · 2023: 129 · 2022: 143 · 2021: 155 · 2020: 180 · 2019: 162 · 2018: 127 · 2017: 152 · 2016: 115 · 2015: 38 · 2014: 1
FWCI
98.98
Type
journal article
Language
en
Open access
Locations
  • Gastroenterology (publishedVersion)
  • PubMed (publishedVersion)
Funders
Crohn's and Colitis Canada
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Inflammatory Bowel Disease
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Epidemiology › Microscopic Colitis
Keywords
fecal microbiota transplantation, ulcerative colitis, remission induction, enema, microbial diversity, inflammatory bowel disease, adverse events
MeSH terms
Adult, Aged, Biological Therapy, Colitis, Ulcerative, Feces, Female, Humans, Male, Middle Aged, Remission Induction, Microbiota

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review